Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Valion Bio (TIVC) EBITDA (2021 - 2025)

Valion Bio has reported EBITDA over the past 5 years, most recently at -$2.5 million for Q3 2025.

  • For Q3 2025, EBITDA fell 73.52% year-over-year to -$2.5 million; the TTM value through Sep 2025 reached -$7.4 million, down 15.32%, while the annual FY2024 figure was -$5.7 million, 31.34% up from the prior year.
  • EBITDA for Q3 2025 was -$2.5 million at Valion Bio, down from -$1.9 million in the prior quarter.
  • Over five years, EBITDA peaked at -$1.1 million in Q2 2021 and troughed at -$3.0 million in Q2 2022.
  • A 5-year average of -$1.9 million and a median of -$1.9 million in 2025 define the central range for EBITDA.
  • Biggest five-year swings in EBITDA: tumbled 186.07% in 2022 and later soared 40.42% in 2024.
  • Year by year, EBITDA stood at -$2.3 million in 2021, then rose by 1.57% to -$2.3 million in 2022, then rose by 0.53% to -$2.2 million in 2023, then skyrocketed by 33.91% to -$1.5 million in 2024, then crashed by 67.43% to -$2.5 million in 2025.
  • Business Quant data shows EBITDA for TIVC at -$2.5 million in Q3 2025, -$1.9 million in Q2 2025, and -$1.5 million in Q1 2025.